# EDGAR Filing Document

**Accession Number:** 0001208906
**File Stem:** 0000914190-25-000021
**Filing Date:** 2025-11
**Character Count:** 7063
**Document Hash:** 26812c4a4f2bc338c4541952a8eba1dc
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000914190-25-000021.hdr.sgml**: 20251103

**ACCESSION NUMBER**: 0000914190-25-000021

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251030

**FILED AS OF DATE**: 20251103

**DATE AS OF CHANGE**: 20251103

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** HIGGINS JOHN L
- **CENTRAL INDEX KEY:** 0001208906

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-17272
- **FILM NUMBER:** 251445326

**MAIL ADDRESS:**
- **STREET 1:** 11119 NORTH TORREY PINES ROAD, SUITE 200
- **CITY:** LA JOLLA
- **STATE:** CA
- **ZIP:** 92037
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** BIO-TECHNE Corp
- **CENTRAL INDEX KEY:** 0000842023
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 411427402
- **STATE OF INCORPORATION:** MN
- **FISCAL YEAR END:** 0630

**BUSINESS ADDRESS:**
- **STREET 1:** 614 MCKINLEY PL N E
- **STREET 2:** SUITE 1500
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55413
- **BUSINESS PHONE:** 612-379-8854

**MAIL ADDRESS:**
- **STREET 1:** 614 MCKINLEY PLACE NE
- **CITY:** MINNEAPOLIS
- **STATE:** MN
- **ZIP:** 55413

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** TECHNE CORP /MN/
- **DATE OF NAME CHANGE:** 19920703

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[ ] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>HIGGINS JOHN L<br><sub>(Last) (First) (Middle)</sub><br>614 MCKINLEY PLACE NE<br><sub>(Street)</sub><br>MINNEAPOLIS, MN 55413<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-10-30 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[ ] Officer (give title below) [ ] Other (specify below)<br>_ _ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>BIO-TECHNE Corp [ TECH ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-10-30 |  | A |  | 1640 | A | $0 | 66876 | D |  |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock Options (Right to Buy) | $25.30 |  |  |  |  |  |  | 2017-10-26 | 2026-10-26 | Common Stock | 15940 |  | 15940 | D |  |
| Stock Options (Right to Buy) | $31.26 |  |  |  |  |  |  | 2018-10-25 | 2027-10-26 | Common Stock | 12500 |  | 12500 | D |  |
| Stock Options (Right to Buy) | $44.96 |  |  |  |  |  |  | 2019-10-24 | 2028-10-25 | Common Stock | 7592 |  | 7592 | D |  |
| Stock Options (Right to Buy) | $50.41 |  |  |  |  |  |  | 2020-10-24 | 2029-10-24 | Common Stock | 8044 |  | 8044 | D |  |
| Stock Options (Right to Buy) | $63.92 |  |  |  |  |  |  | 2021-10-28 | 2030-10-29 | Common Stock | 6028 |  | 6028 | D |  |
| Stock Options (Right to Buy) | $128.81 |  |  |  |  |  |  | 2022-10-27 | 2031-10-28 | Common Stock | 2532 |  | 2532 | D |  |
| Stock Options (Right to Buy) | $73.94 |  |  |  |  |  |  | 2023-10-26 | 2032-10-27 | Common Stock | 3460 |  | 3460 | D |  |
| Stock Options (Right to Buy) | $61.51 |  |  |  |  |  |  | 2024-10-24 | 2033-10-26 | Common Stock | 3937 |  | 3937 | D |  |
| Stock Options (Right to Buy) | $68.37 |  |  |  |  |  |  | 2025-10-24 | 2034-10-24 | Common Stock | 3511 |  | 3511 | D |  |
| Stock Options (Right to Buy) | $60.96 | 2025-10-30 |  | A |  | 3777 |  | <sup>(1)</sup> | 2035-10-30 | Common Stock | 3777 | $0 | 3777 | D |  |

---

### Footnotes:

(1) The option vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.

**Signature:** /s/ Andrew Nick as Attorney-in-Fact for John L. Higgins pursuant to Power of Attorney previously filed  
**Date:** 2025-11-03

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**